The Peptides Pivot: Email + Blog

An FDA Panel Just Voted to Give Four Peptides Back

For months we've told you this fight was coming. On July 23, it turned. Here's what happened, who won it, and why it matters to the Black Forest family.

I don't usually stop a series halfway through. Today I'm making an exception.

I was going to spend this week telling you about parasites. That will have to wait, because the fight we've been talking about for months, the one we've gone to Washington for, just turned a corner I wasn't sure we'd reach.

If you've read along since the beginning, you know the shape of it: the NPA's letter to the FDA, the piece on how Congress and the industry have been moving to control biology, the one where I showed you that restoring peptides and restricting your supplements were the same fight in two masks. This is the next chapter. For once it's a good one.

Before the vote, let me tell you why this was never abstract for me.

I keep hearing the same story from men in this community. A guy in his fifties, told by a doctor he trusts that a peptide might help an injury that won't heal, then told in the same breath that he can't get it here anymore, not legally and not safely. So he does what people do when the front door is locked. He orders a vial off a website that stamps "not for human consumption" on the label to protect itself, and he hopes what's inside is what it says.

He isn't reckless. He was failed by a system that pulled a legal, supervised option off the table and left him a gray market instead. That man is who I was thinking about yesterday. Here is exactly what happened, with the receipts.

What just happened

On Wednesday, July 23, the FDA's own Pharmacy Compounding Advisory Committee sat down to reconsider. The agency's staff scientists argued to keep the restrictions. The committee overruled them and voted to recommend giving four peptides back:

• BPC-157: 8 to 6
• KPV: 8 to 6
• TB-500: 8 to 6
• MOTS-c: 7 to 5

Three more went to a vote the next day. A federal advisory panel looked at its own agency's caution and sided with access. That does not happen. Yesterday it did. It was a recommendation, not a rule, and I'll be straight below about what that does and doesn't mean. But the direction is real. (NPR; NBC News; RAPS)

I'll be straight about the panel, too, because you'll hear it from critics: the FDA seated new members in June, several with ties to peptide medicine, and reporters noted most of the yes votes came from members with industry connections. I'll let the other side spend its energy arguing that the one time a panel voted for access, the deck must have been stacked. For twenty years the table tilted the other way and nobody called a hearing. (STAT; NBC News)

What was taken, and how

To understand why that vote matters, you have to know what was taken. On September 29, 2023, the FDA placed roughly two dozen peptides into what it calls "Category 2" of its compounding list: substances it says "raise significant safety risks." That one classification barred pharmacies from making them. The list named BPC-157, TB-500, KPV, and MOTS-c, alongside more than a dozen others.

Read the language carefully. "Significant safety risk" is not "proven to cause harm." The FDA never published the methodology behind those determinations. Compounders asked; the agency wouldn't divulge it. Compounds clinics around the world have used for years were reclassified out of your reach, not by a finding you could challenge, but by a category you were never shown the math for.

That is how control works here. Not with a ban you can see and fight. With paperwork you were never meant to read.

Why the door was so heavy

The part that explains everything is who that agency answers to. It is not you:

• In fiscal 2024, industry user fees funded roughly 48% of the FDA's entire budget, and about two-thirds of its human-drug review program. The companies applying to sell patented medicine pay for most of what it costs to review their own applications. (Congressional Research Service R44750; HHS/ASPE)
• In 2024, pharmaceuticals and health products was the single biggest-spending lobbying industry in America at $391.6 million, a title it has held every year since 1999. (OpenSecrets)
• The process moves like tar: the average notice-and-comment rulemaking in the GAO's review took just over four years, individual rules running from one to thirteen. (GAO-09-205)

Slow isn't an accident. Slow is how a well-funded incumbent outlasts a movement. That is the machine that decided you couldn't have these compounds.

The same fight, already proven

If you think peptides are an isolated case, look at what's already happened:

• NMN. In 2022 the FDA declared this longevity compound could no longer be sold as a supplement, on a technicality: a pharmaceutical company had started studying it as a medicine. The industry fought back, the NPA led the legal challenge, and people like you kept the pressure on. In 2025 the FDA backed down and confirmed NMN is lawful again. They ran the same play they ran on peptides. It only failed because people pushed. (Nutritional Outlook 2022; Venable 2025; NPA)
• Your shelf, state by state. More than a dozen states have introduced bills restricting weight-loss and muscle-building supplements. New York's took effect in April 2024, and its ingredient list names creatine. New Jersey's cleared its Assembly; California's governor vetoed his. (National Law Review; Venable; Holland & Knight)

A coordinated squeeze, state and federal, with peptides as the sharpest edge.

Who actually won this

I want to be careful, because the easy story is the wrong one. The easy story says Washington handed this to you. Robert F. Kennedy Jr. did carry it into the halls, and he's said plainly he intends to roll these restrictions back. The NPA pushed. Doctors testified. Lawyers filed. They all deserve credit.

But none of them started this. You did.

The Black Forest family has been in this fight since day one. You wrote the letters. You called the offices. You forwarded the emails your brother-in-law thought were crazy. You refused to take no when taking no was easier. Washington doesn't move unless something pushes it, and for years, you were the thing pushing. So when I say we won one yesterday, I mean we. All of us.

The honest part

Now the truth, the way I always give it, even when it's not the exciting version. This is not the finish line. A panel's recommendation is not a rule, and it isn't binding; the FDA still makes the final call. What happened yesterday begins that four-year machine, and the same interests that buried these compounds will fight every step of it.

These peptides are not on a shelf waiting for you today, and they won't be tomorrow. The gray market I told you about at the start is still there, and it's still a gamble. Anyone who tells you the fight is over, or that you can safely shortcut it today, is selling you something, and it isn't the truth. (RAPS; Frier Levitt)

What it means for you

What changed is the direction. For the first time in years, the momentum points toward a world where you and a doctor you trust decide what belongs in your body. Not a committee. Not a lobbyist. Not a system that profits when you stay unwell.

We saw this coming. And while we were writing to you about it, we were quietly building for the day this door opened: a way to do this right, with real oversight and a supply chain you can actually trust. I won't promise a date, because the rules aren't written yet. But when it's ready, you'll be the first to know. That's a promise I can keep.

One door

Freedom doesn't come back all at once. It comes back one day at a time. Yesterday, a door that hadn't moved in years finally did. And you are the reason.

We'll get back to the parasites soon. That fight matters too. But today, we reclaim something. Mark it.

Antonio
Founder, Black Forest Supplements

Sources: FDA 503A bulk-substances list & Restore Health Consulting (2023 Category 2 action) · CRS R44750 + HHS/ASPE (FDA user fees) · OpenSecrets (2024 lobbying) · GAO-09-205 (rulemaking timeline) · Nutritional Outlook 2022, Venable 2025, NPA (NMN) · National Law Review, Venable, Holland & Knight (state bills) · Frier Levitt (gray market) · NPR, NBC News, RAPS, STAT (July 23 vote).